Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Cash & Current Investments (2020 - 2025)

Mirum Pharmaceuticals has reported Cash & Current Investments over the past 6 years, most recently at $383.3 million for Q4 2025.

  • Quarterly results put Cash & Current Investments at $383.3 million for Q4 2025, up 36.75% from a year ago — trailing twelve months through Dec 2025 was $383.3 million (up 36.75% YoY), and the annual figure for FY2025 was $383.3 million, up 36.75%.
  • Cash & Current Investments for Q4 2025 was $383.3 million at Mirum Pharmaceuticals, up from $375.5 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for MIRM hit a ceiling of $383.3 million in Q4 2025 and a floor of $132.1 million in Q1 2023.
  • Median Cash & Current Investments over the past 5 years was $290.5 million (2022), compared with a mean of $289.3 million.
  • Biggest five-year swings in Cash & Current Investments: crashed 60.4% in 2023 and later skyrocketed 129.3% in 2024.
  • Mirum Pharmaceuticals' Cash & Current Investments stood at $256.5 million in 2021, then fell by 1.88% to $251.7 million in 2022, then rose by 13.75% to $286.3 million in 2023, then dropped by 2.1% to $280.3 million in 2024, then soared by 36.75% to $383.3 million in 2025.
  • The last three reported values for Cash & Current Investments were $383.3 million (Q4 2025), $375.5 million (Q3 2025), and $304.6 million (Q2 2025) per Business Quant data.